Umeclidinium: once-daily LAMA in COPD
Umeclidinium (brand name Incruse Ellipta, in fixed combinations with vilanterol as Anoro Ellipta and with vilanterol and fluticasone furoate as Trelegy Ellipta) is a long-acting muscarinic receptor antagonist (LAMA) for once-daily inhalation in chronic obstructive pulmonary disease (COPD). Approved in the EU in 2014, umeclidinium is part of the standard group of modern bronchodilators.
Compared with tiotropium, the oldest LAMA, umeclidinium has a similar profile with once-daily use through the Ellipta inhaler. The dry-powder system is easy to handle and only requires a single step to prepare the inhalation, supporting adherence.
Mechanism of action
Umeclidinium is a quaternary ammonium anticholinergic with high affinity to all five muscarinic receptor subtypes (M1 to M5); clinically relevant is mainly inhibition of M3 in bronchial smooth muscle. Binding to M3 is more slowly reversible than to M2, leading to a selective bronchodilation lasting over 24 hours.
By inhibiting vagally mediated bronchoconstriction, the airways widen, the work of breathing falls, alveoli are better ventilated and dyspnoea is eased. Additional reduction of mucus secretion makes coughing up easier.
Umeclidinium is mainly metabolised hepatically (CYP2D6) and eliminated biliarily. Systemic exposure after inhalation is low, minimising systemic anticholinergic effects.
Indications
- Maintenance therapy in COPD: in symptomatic patients to ease breathlessness, reduce symptoms and prevent exacerbations
- Triple therapy in COPD: in the fixed combination Trelegy with vilanterol and fluticasone furoate, especially in patients with frequent exacerbations or asthma-COPD overlap
- Asthma: umeclidinium is not approved as monotherapy in asthma, but can be considered as part of a triple therapy in severe asthma
Selection follows GOLD recommendations and individual disease severity.
Dosing and administration
Standard dose: 55 µg once daily (corresponding to 65 µg umeclidinium bromide) by inhalation from the Ellipta inhaler.
Use:
- Open the inhaler; a dose is automatically prepared (audible click)
- Place lips firmly around the mouthpiece, inhale long and steadily through the mouthpiece
- Hold breath for 3 to 4 seconds
- Close the inhaler
- If needed, rinse mouth with water to reduce dry mouth
The Ellipta inhaler has a counter showing remaining doses; the last dose is signalled by a red field.
Take once a day at the same time. If a dose is missed, take the next dose at the regular time the next day; do not double up.
Side effects
Common: nasopharyngitis, respiratory tract infections, headache, cough, dry mouth, constipation, sinusitis.
Uncommon: tachycardia, atrial fibrillation, palpitations, rash, pruritus, taste changes, dysphonia.
Rare: narrow-angle glaucoma attack, urinary retention, paradoxical bronchospasm, allergic reactions including angioedema.
Important points:
- Umeclidinium is not suitable for treating acute breathlessness; short-acting bronchodilators are needed
- Patients with narrow-angle glaucoma or prostatic hyperplasia should be informed about symptoms requiring medical review
- If paradoxical bronchospasm occurs after inhalation, stop therapy
Interactions
- Other anticholinergics (tiotropium, glycopyrronium, aclidinium, ipratropium): additive anticholinergic effect, combination not recommended
- Sympathomimetics (LABA, SABA): sensible combination for bronchodilation
- Inhaled corticosteroids: sensible combination with frequent exacerbations
- Strong CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion): theoretically raised levels, clinically rarely relevant under inhaled use
Special considerations
Pregnancy: limited data, use only on clear indication after benefit-risk assessment.
Breastfeeding: passage into milk insufficiently studied.
Narrow-angle glaucoma: raised intraocular pressure possible. Patients should be informed about symptoms such as acute eye pain, redness, blurred vision, halos around lights.
Prostatic hyperplasia: risk of urinary retention, especially in men with existing symptoms.
Renal impairment: no dose adjustment required.
Hepatic impairment: no adjustment with moderate impairment; data limited in severe impairment, caution.
Inhalation technique: regular check. The Ellipta inhaler is easy to use, but common errors are insufficient inhalation or too short breath holding. Pharmacy support and training material help adherence.
Daily routine: patients often benefit from integrating inhalation into a fixed routine, such as right after waking or brushing teeth, to remember the once-daily dose reliably.
Related substances
- Aclidinium, twice-daily LAMA
- Glycopyrronium, another LAMA
- Olodaterol, once-daily LABA
- Fluticasone, ICS in Trelegy
- Formoterol fumarate dihydrate, common LABA
Frequently asked questions
How does umeclidinium differ from tiotropium?
Both LAMAs are once daily and have a comparable clinical profile. Tiotropium has been on the market for decades, while umeclidinium is delivered via the Ellipta inhaler, rated in studies as particularly easy to use. The choice often depends on inhaler preference, comorbidities and existing inhalation strategy.
What about acute breathlessness?
Umeclidinium acts slowly and is maintenance therapy. For acute breathlessness short-acting bronchodilators such as salbutamol or ipratropium are used. If acute episodes become more frequent or rescue medication is insufficient, the baseline therapy should be reviewed.
What is the Trelegy concept?
Trelegy Ellipta contains three substances in a single inhaler: umeclidinium (LAMA), vilanterol (LABA) and fluticasone furoate (ICS). This triple therapy is used in COPD patients with frequent exacerbations or asthma-COPD overlap. Advantage: only one inhaler, once daily, supporting adherence.
Can I take umeclidinium long term?
Yes, umeclidinium is designed as long-term maintenance. Regular use is important since irregular use compromises symptom control. With stable symptoms over a longer period, the treating physician can consider whether therapy adjustments are useful.
Sources
- EMA Incruse Ellipta (umeclidinium) EPAR
- BfArM Federal Institute for Drugs and Medical Devices
- AWMF NVL COPD and GOLD guideline
- Gelbe Liste umeclidinium monograph
Legal notice and disclaimer
The information on this page is provided for general information purposes only and does not constitute medical advice, diagnosis or treatment recommendation. It does not replace the advice of a licensed physician or pharmacist. Medicines should only be used after a doctor's prescription or pharmacy supply. All information is based on summaries of product characteristics and accepted scientific sources at the time of writing; the current SmPC of the manufacturer is always decisive. Sanoliste accepts no liability for completeness, timeliness or accuracy. In a medical emergency, dial the emergency number 112.